<DOC>
	<DOCNO>NCT02297867</DOCNO>
	<brief_summary>The aim investigator study investigate safety efficacy autologous ADSCs clinical treatment liver cirrhosis .</brief_summary>
	<brief_title>Clinical Trial Study About Human Adipose-Derived Stem Cells Liver Cirrhosis</brief_title>
	<detailed_description>One milliliter cell suspension inject intrahepatically sonographic guidance use gauge-18 needle .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>1 . Liver cirrhosis investigator age 20 80 year ( inclusive ) . 2 . Investigators without Mandatory Communicable Disease ( HBV , HCV , HIV , syphilis ) 3 . Investigators without rare disorder 4 . Coagulation normality 5 . Investigators without autoimmune disorder 6 . Investigators without Acquired Immune Deficiency Syndrome 7 . Investigators without cancer 8 . Investigators BMI ＞ 15 1 . Pregnant woman 2 . Investigators acute stroke one month unconsciousness 3 . Investigators acute myocardial infarction acute heart failure 4 . Investigators serious liver dysfunction coagulation dysfunction ascites mild high 5 . Investigators acute respiratory failure pneumonia 6 . Kidney Failure : BUN ＞ 50 7 . Anemia : Hematocrit ＜ 25 8 . Investigators diagnose liver cancer liver metastatic carcinoma 9 . Investigators liver abscess 10 . Investigators acute Hepatitis 11 . Investigators acute infective 12 . Liver cirrhosis patient HBV HCV 13 . Investigators diagnose carcinoma receive treatment 14 . Investigators Schizophrenia melancholia 15 . Investigators receive serious surgical operation 3 month 16 . Investigators unable control hypertension ( SBP ＞ 180 mmHg , DBP ＞ 110 mmHg ) diabetes ( AC sugar ＞ 200 mg/dl ) 17 . Others ca n't fit trial evaluate investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>